spacer
home > ict > autumn 2009 > asean all-stars
PUBLICATIONS
International Clinical Trials

ASEAN All-Stars

 

The clinical trial landscape has changed dramatically over the past decade. Whereas at the turn of the century, almost all clinical trial research was carried out in the US and western Europe, US-based drug sponsors indicate that up to 50 per cent of studies are now conducted outside of the US and expect that figure to increase to 65 per cent within three years (1). In 1990, clinical trials were conducted in about 28 countries worldwide. In September 2009, the FDA was regulating 78,276 trials in 172 countries, and the European Medicines Agency (EMEA) expects the trend to conduct more clinical trials in developing nations to increase in years to come.

There are a number of reasons for this shift. Lower costs, access to large numbers of treatment-naďve patients, the potential for fast patient recruitment and the opportunity to expand their presence in emerging markets are among the top reasons pharmaceutical companies are now conducting trials in developing nations. South-east Asia is an increasingly popular destination because it offers all of these benefits.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gary Muddyman is the Managing Director and CEO of Conversis, a leading provider of globalisation, internationalisation, localisation and translation services, specialising in the life sciences sector. Gary started Conversis back in 2003 with the intention of advancing the understanding and use of localisation and translation as a strategic business tool. Before that, he spent 16 years at HSBC.
spacer
Garry Muddyman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline

Sanofi announced today an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer, with a total payment of $90 million for three years plus additional research milestone-based payments.
More info >>

White Papers

Challenges of Analytical Method Transfer in the Pharmaceutical Industry

RSSL

The development and validation of suitable analytical methods is a critical part of the overall drug-development life-cycle. For the majority of products, particularly those that are clinically successful, the transfer of the analytical method between laboratories will be required. This process is designed to verify that a given laboratory is capable of performing a test method for its intended purpose. This can be performed either internally (at the same company), or, with the on-going increasing trend in outsourcing, to an external Contract Research or Development organisation (CRO or CDO).
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement